NCT05401110 2026-03-04
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Cedars-Sinai Medical Center
Phase 1 Recruiting
Clinical Trials
23 trialsNCT02520063 2026-02-06
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT05534646 2026-02-02
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT02429843 2021-06-28
A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer
University of Alabama at Birmingham
Phase 1 Completed
NCT03418324 2020-12-30
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT01806064 2020-10-19
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Terminated
NCT02560779 2020-07-17
Trial of TRC105 and Sorafenib in Patients With HCC
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT03181308 2020-06-24
Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
Tracon Pharmaceuticals Inc.
Phase 1 Completed
NCT01975519 2020-05-20
A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT02979899 2020-05-12
TAPPAS
Tracon Pharmaceuticals Inc.
Phase 3 Completed
NCT03780010 2019-10-28
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
Tracon Pharmaceuticals Inc.
Phase 1 Completed
NCT02664961 2019-07-23
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Tracon Pharmaceuticals Inc.
Phase 2 Terminated
NCT01564914 2019-06-12
105GM201
Tracon Pharmaceuticals Inc.
Phase 2 Completed
NCT02396511 2019-06-11
TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
Tracon Pharmaceuticals Inc.
Phase 2 Completed
NCT01326481 2019-03-18
TRC105
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT01381861 2019-03-05
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Tracon Pharmaceuticals Inc.
Phase 2 Completed
NCT01306058 2019-01-23
Sorafenib and TRC105 in Hepatocellular Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01332721 2018-12-05
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
Tracon Pharmaceuticals Inc.
Phase 1 Completed
NCT01727089 2018-08-28
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01648348 2018-05-23
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01090765 2018-05-22
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01375569 2017-07-28
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01328574 2017-01-13
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed